NEW YORK (GenomeWeb) – Horizon Discovery today announced an agreement with Swift Biosciences to incorporate Horizon's human genomic reference standards into Swift's Accel-Amplicon 56G Oncology Panel.
Swift will include Horizon's HDx Quantitative Multiplex Reference Standard material as a positive control in its single-tube, 56-gene panel. The assay covers genes clinically relevant to cancer and generates sequencing libraries for use on common next-generation sequencing platforms from both formalin-fixed, paraffin-embedded and circulating, cell-free DNA samples.
Financial and other details of the agreement were not disclosed.
"The Accel-Amplicon 56G panel combined with the Horizon reference standards offer a very powerful tool for detecting clinically important mutations, which is particularly important when sequencing samples that are very limited in availability," Hong Yin, a researcher at Louisiana State University's Feist-Weiller Cancer Center, said in a statement.
Earlier this month, Horizon signed a deal for Bioké to distribute the reference standards in The Netherlands. In June, Horizon partnered with CareDx to develop the reference standards for cell-free and circulating DNA.